Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-85
SponsorLi An

About this trial

This study is planned to be conducted based on the cohort of patients with severe chronic obstructive pulmonary disease in our hospital. Based on gut microbiota, random forest was used to search for potential diagnostic biomarkers in patients with frequent acute exacerbation and controls with non frequent acute exacerbation; Construct a frequent acute exacerbation risk prediction model using random forest, support vector machine, and BP neural network models. The development of this study will provide valuable references for the clinical classification and prognosis evaluation of chronic obstructive pulmonary disease (COPD), and improve the health level of COPD patients by further searching for treatable targets.

Eligibility criteria

Qualifiers

Patients who meet the diagnostic criteria for COPD of the global initiative for chronic obstructive lung diseases (GOLD 2022) and GOLD grading Ⅲ - Ⅳ (FEV1/FVC<70%, FEV1% predicted value ≤ 50% after Bronchiectasis)

Age>40 years old

COPD stable for more than 4 weeks

Short acting Bronchiectasis was not used within 24 hours before this experiment, long acting Bronchiectasis was not used within 48 hours, and glucocorticoids were not used throughout the body in the past month

Disqualifiers

Asthma, active pulmonary tuberculosis, interstitial pneumonia and severe Bronchiectasis

Complicated with serious diseases (acute infection, diabetes, stroke, heart disease, liver and kidney dysfunction, cancer or autoimmune disease)

History of chronic diarrhea or constipation

History of Gastrointestinal Surgery

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

365 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Li An

Lead sponsor

Beijing Chao Yang Hospital

Sponsor institution